Vincent O. Dezentjé YOU? Author Swipe

Last 10y

Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis Open

Karan Parekh, Kim van der Zande, Sarah W.S. Ng, Cameron Herberts, Edmond M. Kwan , et al. · 2025

No significant differences in CBR or time-to-event endpoints were observed between cabazitaxel and ARPIs. However, prior ARPI exposure, a higher baseline ctDNA fraction, and PTEN alterations were strongly prognostic.

Yttrium-90 transarterial radioembolization as an ablative approach for oligoprogressive breast cancer: a case report Open

Charlotte Schneider, Tarik Baetens, Marloes van Dongen, Geerard L. Beets, F. Muñoz , et al. · 2025

P041: Distinguishing Second Ipsilateral Locoregional Breast Cancer as True Recurrence or New Primary: A Comparison of Clinicopathological Classification and Molecular Clonality Analysis Open

T. Snellen, Vincent O. Dezentjé, T. Wiersma, Miet Peeters · 2025

Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort Open

Cornelia AM Almekinders, Lishi Lin, Jos H. Beijnen, Gabe S. Sonke, Alwin D. R. Huitema , et al. · 2024

The efficacy of screening with FDG-PET/CT for distant metastases in breast cancer patients scheduled for neoadjuvant systemic therapy Open

Jetske L B Gunster, Frederieke van Duijnhoven, Astrid N. Scholten, Carolien H. Smorenburg, Vincent O. Dezentjé , et al. · 2024

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD Open

Jonathan E. Knikman, Qinglian Zhai, Carin A.T.C. Lunenburg, Linda M. Henricks, Stefan Böhringer , et al. · 2024

Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan Open

Dirk Jan A. R. Moes, Jeroen J. M. A. Hendrikx, Henk‐Jan Guchelaar, Ron H.J. Mathijssen, Jurriaan Bakker , et al. · 2024

A Genome‐Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early‐Stage Breast Cancer Patients Open

Anabel Sanchez‐Spitman, Stefan Böhringer, Vincent O. Dezentjé, Hans Gelderblom, Jesse J. Swen , et al. · 2024

Tamoxifen is part of the standard of care of endocrine therapy for adjuvant treatment of breast cancer. However, survival outcomes with tamoxifen are highly variable. The concentration of endoxifen, the 30–100 times more potent metabolite …

Figure S3 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

Bland-Altman plot of endoxifen (in µg/l) at 3 months and at 6 months.

Figure S3 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

Bland-Altman plot of endoxifen (in µg/l) at 3 months and at 6 months.

Figure S2 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

Flowchart of patients who were included/excluded from the study.

Figure S1 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

Quality of Life Questionnaire

Table S2 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

Results of ordinal regression models of the questionnaire items on endoxifen level after multiple imputation.

Data from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

Purpose: Levels of endoxifen, the most active metabolite of tamoxifen, vary by the highly polymorphic cytochrome P450 (CYP) 2D6 enzyme. We prospectively investigated tamoxifen efficacy by serum endoxifen levels and the tamoxifen act…

Table S1 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

List of participating centres and number of patients included.

Figure S4 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

Kaplan-Meier curves stratified by endoxifen levels using a quartile split.

Data from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

Purpose: Levels of endoxifen, the most active metabolite of tamoxifen, vary by the highly polymorphic cytochrome P450 (CYP) 2D6 enzyme. We prospectively investigated tamoxifen efficacy by serum endoxifen levels and the tamoxifen act…

Figure S2 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

Flowchart of patients who were included/excluded from the study.

Table S2 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

Results of ordinal regression models of the questionnaire items on endoxifen level after multiple imputation.

Figure S1 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

Quality of Life Questionnaire

Table S1 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

List of participating centres and number of patients included.

Figure S4 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial Open

Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme , et al. · 2023

Kaplan-Meier curves stratified by endoxifen levels using a quartile split.

Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer Open

Rieneke T. Lugtenberg, Stefanie de Groot, Danny Houtsma, Vincent O. Dezentjé, Annelie Vulink , et al. · 2023

Background: There is little evidence that supports the registered high dose of dexamethasone used around docetaxel. However, this high dose is associated with considerable side effects. This study evaluates the feasibility of reducing the …

Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group Open

Simon Peter Gampenrieder, Vincent O. Dezentjé, Matteo Lambertini, Alexandre de Nonneville, Maximilian Marhold , et al. · 2022

Real-world data of HER2-low metastatic breast cancer: A population based cohort study Open

Emily I. Holthuis, Gerard T. Vondeling, Josephina G. Kuiper, Vincent O. Dezentjé, Mats Rosenlund , et al. · 2022

Substantial proportion of patients had a HER2-low breast cancer. No clear differences in survival were found when comparing HER2 and HR status. Getting more granular insights in the level of HER2 expression and addressing HER2-low as a sep…

177P Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT) Open

Simon Peter Gampenrieder, Vincent O. Dezentjé, Matteo Lambertini, Alexandre de Nonneville, Maximilian Marhold , et al. · 2022

Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial Open

S.B. Vliek, Iris Noordhoek, Elma Meershoek‐Klein Kranenbarg, Annelot G.J. van Rossum, Vincent O. Dezentjé , et al. · 2022

PURPOSE For postmenopausal patients with breast cancer, previous subgroup analyses have shown a modest benefit from adjuvant bisphosphonate treatment. However, the efficacy of oral nitrogen-containing bisphosphonates such as ibandronate is…

RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Open

Emmy Boerrigter, Guillemette E. Benoist, Inge M. van Oort, Gerald W. Verhaegh, Anton F. J. de Haan , et al. · 2021

Treatment evaluation in metastatic castration-resistant prostate cancer is challenging. There is an urgent need for biomarkers to discriminate short-term survivors from long-term survivors, shortly after treatment initiation. Thereto, the …

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223 Open

Sushil K. Badrising, Rebecca D. Louhanepessy, Vincent van der Noort, Jacobien M. Kieffer, Jules L.L.M. Coenen , et al. · 2021

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse Open

Anabel Sanchez‐Spitman, Jesse J. Swen, Vincent O. Dezentjé, Dirk Jan A. R. Moes, Hans Gelderblom , et al. · 2021

CYP2C19*2 and CYP2C19*17 might influence tamoxifen metabolism and clinical outcome. Our aim was to investigate the effect of CYP2C19 genotypes on tamoxifen concentrations and metabolic ratios (MRs) and breast cancer recurrence in a large c…

Fetching topic information...